Bryan Garnier - BASILEA PHARMACEUTICA (BSLN.S) BASILEA PHARMACEUTICA BUY | CHF102 With several catalysts in sight, it is time to jump in

Report

Bryan Garnier

Victor Floc’h

BASILEA PHARMACEUTICA BUY | CHF102 With several catalysts in sight, it is time to jump in

BASILEA PHARMACEUTICA BUY | CHF102 With several catalysts in sight, it is time to jump in

PoC in iCCA marks the start of an exciting year for derazantinib
Biggest catalyst of the year will be UC
Gastric cancer could be a first-to-market opportunity

11/02/2021 3 EN

Underlying

BASILEA PHARMACEUTICA

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Victor Floc’h

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Bryan Garnier

BASILEA PHARMACEUTICA (BUY, TP CHF91) | Positive phase III results for Cresemba in Japan

July 26, 2021 July 26, 2021 3 EN

Bryan Garnier

BASILEA (BUY, TP CHF91) | Lisavanbulin’s market opportunity strengthened by new epidemiology data

June 7, 2021 June 7, 2021 1 EN

Cinclus Pharma: start of phase 3 reiterated for Q3'25

Cinclus Pharma reported its Q1 results which focused on balance sheet items and a recap of corporate achievements for the quarter, with a cash position at SEK523.9m and an EBIT at SEK(47.519m). With the current cash position and operational cash burn, we forecast a runway into H1 2027. On the opera

15h / 22m 15h / 22m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

HydrogenPro: LONGi Hydrogen to invest NOK70m

HydrogenPro announced yesterday that LONGi Hydrogen has obtained the necessary Overseas Direct Investment (ODI) approval in China to invest NOK70m in the company. This follows an announcement made in December 2024 whereby HydrogenPro had secured (i) NOK70m in new equity from its existing strategic

15h / 40m 15h / 40m 1 EN

Clement Genelot

Clement Genelot

Just Eat Takeaway: tender to the offer

Following the publication of the offer memorandum yesterday by Prosus and the launch of the tender offer today until 29th July, we have withdrawn our Neutral rating and advise shareholders to tender their shares to the offer.1/ We consider the offer as generous with implied c.11.5x EV/EBITDA 2025e

15h / 58m 15h / 58m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BASILEA PHARMACEUTICA BUY | CHF102 With several catalysts in sight, it is time to jump in

Monthly LMI Update Independent Investment Research

BASILEA PHARMACEUTICA (BUY, TP CHF91) | Positive phase III results for Cresemba in Japan

BASILEA (BUY, TP CHF91) | Lisavanbulin’s market opportunity strengthened by new epidemiology data

Cinclus Pharma: start of phase 3 reiterated for Q3'25

HydrogenPro: LONGi Hydrogen to invest NOK70m

Just Eat Takeaway: tender to the offer

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe